Sign up to save your podcasts
Or
Share 20 Years of EGFR
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
20 Years of EGFR
In this episode of The Cancer Letter Podcast, we convene a special panel of people who have played a role in the discovery of the EGFR mutation in lung cancer.
The panel is moderated by Suresh S. Ramalingam, a lung cancer expert, executive director of Winship Cancer Institute of Emory University, and editor-in-chief of the journal Cancer. Other members of the panel include:
- Katerina Politi, PhD, Joseph A. and Lucille K. Madri Professor of Pathology, Scientific director, Center for Thoracic Cancers, Co-leader, Cancer Signaling Networks, Yale Cancer Center
- Pasi A. Jänne, MD, PhD, Senior vice president for Translational Medicine, Director, Belfer Center for Applied Cancer Science, Director, Chen-Huang Center for EGFR Mutant Lung Cancers, Senior physician, Professor of Medicine, Harvard Medical School; David M. Livingston, MD, Chair, Dana-Farber Cancer Institute
- Ramaswamy Govindan, MD, Anheuser Busch Endowed Chair in Medical Oncology, Professor of medicine, Division of Oncology, Director, Section of Medical Oncology, Washington University School of Medicine
- David P. Carbone, MD, PhD, Barbara J. Bonner Chair in Lung Cancer Research, Director, James Thoracic Center, Co-leader, Translational Therapeutics Program, Ohio State University Comprehensive Cancer Center
May 2024 marked the 20th anniversary of the publication of papers on the role of the EGFR mutation in lung cancer. The discovery of the role of the EGFR mutation in lung cancer was a seminal event that changed the history of the disease and can be traced back to one reason why cancer mortality has been declining in the U.S.
We’ve spent a year exploring the significance of the EGFR story, a story that is 20 years old and that is still ongoing. This story, like no other, shows the importance of the interaction between basic researchers, translational researchers, pharmaceutical companies, NCI, and regulators—especially at FDA. This discovery saved and continues to save lives, and it revolutionized medicine. It’s especially important to highlight this now, as the delicate balance of oncology research is being threatened.
This episode is part of a series.
A full transcript of this podcast is available at https://cancerletter.com/podcastc/20250214_5/
View all episodes
By The Cancer LetterIn this episode of The Cancer Letter Podcast, we convene a special panel of people who have played a role in the discovery of the EGFR mutation in lung cancer.
The panel is moderated by Suresh S. Ramalingam, a lung cancer expert, executive director of Winship Cancer Institute of Emory University, and editor-in-chief of the journal Cancer. Other members of the panel include:
- Katerina Politi, PhD, Joseph A. and Lucille K. Madri Professor of Pathology, Scientific director, Center for Thoracic Cancers, Co-leader, Cancer Signaling Networks, Yale Cancer Center
- Pasi A. Jänne, MD, PhD, Senior vice president for Translational Medicine, Director, Belfer Center for Applied Cancer Science, Director, Chen-Huang Center for EGFR Mutant Lung Cancers, Senior physician, Professor of Medicine, Harvard Medical School; David M. Livingston, MD, Chair, Dana-Farber Cancer Institute
- Ramaswamy Govindan, MD, Anheuser Busch Endowed Chair in Medical Oncology, Professor of medicine, Division of Oncology, Director, Section of Medical Oncology, Washington University School of Medicine
- David P. Carbone, MD, PhD, Barbara J. Bonner Chair in Lung Cancer Research, Director, James Thoracic Center, Co-leader, Translational Therapeutics Program, Ohio State University Comprehensive Cancer Center
May 2024 marked the 20th anniversary of the publication of papers on the role of the EGFR mutation in lung cancer. The discovery of the role of the EGFR mutation in lung cancer was a seminal event that changed the history of the disease and can be traced back to one reason why cancer mortality has been declining in the U.S.
We’ve spent a year exploring the significance of the EGFR story, a story that is 20 years old and that is still ongoing. This story, like no other, shows the importance of the interaction between basic researchers, translational researchers, pharmaceutical companies, NCI, and regulators—especially at FDA. This discovery saved and continues to save lives, and it revolutionized medicine. It’s especially important to highlight this now, as the delicate balance of oncology research is being threatened.
This episode is part of a series.
A full transcript of this podcast is available at https://cancerletter.com/podcastc/20250214_5/